Generate Biomedicines prices $400M IPO to fund AI‑designed asthma drug

Generate Biomedicines priced 25 million shares at $16 each, raising $400 million in a priced IPO and saying proceeds will bankroll late‑stage development of its lead AI‑designed therapy. With an underwriter overallotment option for 3.75 million more shares, the deal could reach $460 million; the company began trading on Nasdaq under the ticker GENB the day after pricing and carried a market value at pricing of about $2.04 billion.

Founded by Flagship Pioneering in 2018, Generate positions itself as a generative‑AI protein therapeutics company that couples machine learning models with high‑throughput experimental validation in a closed design‑build‑test‑learn loop. The company reports it has advanced three computationally engineered proteins into human testing, the most advanced being GB‑0895, an investigational long‑acting monoclonal antibody that targets thymic stromal lymphopoietin (TSLP) for severe asthma.

Generate’s prospectus allocates roughly $300 million of IPO proceeds to the two ongoing pivotal Phase 3 trials of GB‑0895, which together are enrolling about 1,600 patients, and about $100 million to a Phase Ib and a separate Phase 1 study exploring the antibody in chronic obstructive pulmonary disease. The company says the Phase 3 studies began late in 2025 and entered a large clinical study early this year, with full enrollment expected by the first half of 2028. The company has described GB‑0895 as long‑acting, with dosing once every six months, and positions it as a potential competitor to AstraZeneca’s tezepelumab.

Goldman Sachs and Morgan Stanley led the book‑running group on the offering, joined by Piper Sandler, Guggenheim Securities and Cantor Fitzgerald. All shares in the offering were primary shares sold by the company rather than by selling stockholders, signaling a capital‑raising focus rather than an early‑investor exit.

The IPO is one of the larger public debuts for an AI‑enabled biotech this year and follows a wave of early‑2026 listings that have tested the market’s appetite for high‑growth, technology‑driven drug developers. Comparable recent raises in the space include Eikon Therapeutics’ roughly $380 million offering and combined industry deals from other emerging biotech issuers. Yet public market conditions remain volatile for growth names, and successful aftermarket performance will hinge on investor reception to clinical readouts and the pace of enrollment.

Generate’s pre‑IPO financing figures vary across public summaries: the company’s earlier rounds are cited as a $370 million Series B in 2021 and a $273 million Series C in 2023, amounts that have been summarized as nearly $700 million of private financing; other summaries place venture backing above $800 million and note roughly $110 million in payments from collaborations with Amgen and Novartis. Separately disclosed collaboration accords include potential deal values reported in the industry as reaching up to roughly $1.9 billion with Amgen and more than $1 billion with Novartis, reflecting the structure of milestone‑heavy partnerships common in biotech.

Generate’s IPO marks a fresh test of investor confidence in AI‑driven discovery platforms: the company is deploying public capital to propel a machine‑designed molecule through pivotal trials that, if positive, could validate a faster, data‑driven approach to protein therapeutics and influence financing patterns across the sector.